Key facts for J2778
- Billing unit
- 0.1 mg
- Ranibizumab injection
- ASP payment limit
- $26.384
- October 2026; -48.4% vs July 2026
- Practitioner MUE
- 10
- MAI 2
- NCCI exposure
- no PTP pairs
- Coverage articles
- 1
- 5 states
TL;DR
HCPCS J2778 is the Level II code for Injection, ranibizumab, 0.1 mg, billed per 0.1 mg. The Medicare Part B ASP payment limit for October 2026 is $26.384 per billing unit, down 48.4% from July 2026. The practitioner MUE allows up to 10 units per date of service (MAI 2), so a full 10-unit day is $263.84 at the current limit. Under OPPS it carries status indicator K in APC 9233. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names ranibizumab: Q5124 (biosimilar ranibizumab-nuna (Byooviz); billed per 0.1 mg); Q5128 (biosimilar ranibizumab-eqrn (Cimerli) from Sandoz Inc.; billed per 0.1 mg); Q5168 (biosimilar ranibizumab-leyk (Nufymco) from Zydus Pharmaceuticals (USA) Inc.; billed per 0.1 mg); J2779 (Susvimo; implant and intravitreal route; billed per 0.1 mg). The ASP crosswalk maps 2 NDCs to it, sold as Lucentis, Lucentis PFS by Genentech, Inc. 1 Medicare coverage article lists the code across 5 states, including A52451.
Medicare Part B payment limit (ASP)
CMS sets the Part B payment limit for J2778 at $26.384 per 0.1 mg for October 2026, derived from manufacturer average sales price plus 6%, compared with $51.09 in July 2026. Beneficiary coinsurance is 20%.
| Quarter | Payment limit | Per | Coinsurance |
|---|---|---|---|
| October 2026 | $26.384 | 0.1 mg | 20% |
| July 2026 | $51.09 | 0.1 mg | — |
NDC to HCPCS billing-unit conversion
The October 2026 ASP crosswalk maps 2 NDCs from 1 labeler to J2778. Report the NDC in the claim's drug segment and bill the number of J2778 units that equals the quantity administered divided by 0.1 mg; the last column gives units per full package.
| NDC | Drug name | Labeler | Package size | Billing units / package |
|---|---|---|---|---|
| 50242-0080-03 | Lucentis | Genentech, Inc. | 0.05 × 1 | 5 |
| 50242-0082-03 | Lucentis PFS | Genentech, Inc. | 0.05 × 1 | 3 |
Medically Unlikely Edits (MUE)
CMS publishes 2 MUE values for J2778. For practitioners the limit is 10 units per date of service with adjudication indicator 2, a date-of-service policy edit: the limit reflects CMS policy and units above it deny even if split across lines; appeals rarely succeed.
| Setting | MUE (units/DOS) | MAI | CMS rationale |
|---|---|---|---|
| Practitioner services | 10 | 2 Date of Service Edit: Policy | Anatomic Consideration |
| Facility outpatient hospital | 10 | 2 Date of Service Edit: Policy | Anatomic Consideration |
MUE for J2778 in every setting opens the lookup with this code filled in, next to any other code on the same claim.
NCCI edits and add-on relationships
No active practitioner PTP pair lists J2778 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.
The counts above are exposure, not answers for a specific claim. Check J2778 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.
J2778 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.
Medicare coverage articles
1 current Medicare Administrative Contractor article lists J2778 in their HCPCS tables, covering 5 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.
| Article | Title | Contractor(s) | States | Related LCD |
|---|---|---|---|---|
| A52451 | Billing and Coding: Ranibizumab, Aflibercept and biosimilars | Wellpoint Federal | CT IL MN NY WI | L33394 |
Diagnoses Medicare contractors cover for J2778
One billing and coding article attaches a covered diagnosis list to J2778: 230 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).
| ICD-10-CM | Description (FY2027) | Articles covering |
|---|---|---|
| E08.311 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema | 1 of 1 |
| E08.319 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema | 1 of 1 |
| E08.3211 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye | 1 of 1 |
| E08.3212 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye | 1 of 1 |
| E08.3213 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral | 1 of 1 |
| E08.3291 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye | 1 of 1 |
| E08.3292 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye | 1 of 1 |
| E08.3293 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral | 1 of 1 |
| E08.3311 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye | 1 of 1 |
| E08.3312 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye | 1 of 1 |
| E08.3313 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral | 1 of 1 |
| E08.3391 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye | 1 of 1 |
| E08.3392 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye | 1 of 1 |
| E08.3393 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral | 1 of 1 |
| E08.3411 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye | 1 of 1 |
Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J2778 are counted here: a group whose instructions name J2778, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.
| Article | Contractor | Groups that apply | Covered codes for J2778 | Full list |
|---|---|---|---|---|
| A52451 | Wellpoint Federal | group 1 applies to J2778 | 230 | On LCD L33394 |
Local coverage policies that list J2778
1 active Local Coverage Determination lists J2778 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.
- Drugs and Biologicals, Coverage of, for Label and Off-Label Uses, LCD L33394 · Wellpoint Federal
Hospital outpatient (OPPS) status
In the October 2026 OPPS Addendum B, J2778 carries status indicator K and is assigned to APC 9233, with a published national unadjusted payment of $26.384. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.
Ambulatory surgical center (ASC) payment
In the October 2026 ASC Addendum BB (covered ancillary services), J2778 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $26.38 per 0.1 mg, paid only when the drug is furnished integral to a covered surgical procedure.
Common denials for J2778 and how to prevent them
For teams evaluating QuickIntell software
Evaluate a coding workflow for J2778
Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
In QuickIntell research
- October 2026 ASP movers report: J2778's payment limit moved -48.4% against July 2026, one of 75 drug codes that moved 20% or more.
- J codes by drug name: Every code for the same drug, generic or brand, in one A-Z index.
Frequently asked questions — HCPCS J2778
What does HCPCS code J2778 describe?
J2778 is defined by CMS as "Injection, ranibizumab, 0.1 mg". Each billing unit represents 0.1 mg, so the units reported on the claim must equal the dose administered divided by that unit.
Is J2778 a CPT code?
No. J2778 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as ranibizumab; CPT codes are five-character codes maintained by the AMA. On a Part B claim J2778 reports the drug itself in 0.1 mg units, and the administration is billed on its own line.
What is the Medicare reimbursement for J2778 in October 2026?
The ASP-based payment limit is $26.384 per 0.1 mg, with 20% beneficiary coinsurance. The July 2026 limit was $51.09. Commercial payers use their own fee schedules.
How many units of J2778 can be billed per day?
The practitioner Medically Unlikely Edit is 10 units per date of service with adjudication indicator 2 (Date of Service Edit: Policy). MAI 2 edits are policy limits and are rarely overturned on appeal. CMS cites "Anatomic Consideration" as the rationale.
Which NDCs map to J2778?
The October 2026 ASP crosswalk lists 2 NDCs from 1 labeler: Lucentis (Genentech, Inc.); Lucentis PFS (Genentech, Inc.). For example NDC 50242-0080-03 (package size 0.05) equals 5 billing units of J2778.
Does J2778 have NCCI bundling edits?
No active practitioner PTP pairs list J2778 as a column-1 or column-2 code in the v323r0 release.
J2778 vs Q5124: what is the difference?
Both are HCPCS Level II codes whose descriptor names ranibizumab. What sets Q5124 apart: biosimilar ranibizumab-nuna (Byooviz); billed per 0.1 mg. J2778 is billed per 0.1 mg, limit $26.384, MUE 10; Q5124 is billed per 0.1 mg, limit $249.493, MUE 10. Report the code whose descriptor matches the product and setting in the record.
J2778 vs Q5128: what is the difference?
Both are HCPCS Level II codes whose descriptor names ranibizumab. What sets Q5128 apart: biosimilar ranibizumab-eqrn (Cimerli) from Sandoz Inc.; billed per 0.1 mg. J2778 is billed per 0.1 mg, limit $26.384, MUE 10; Q5128 is billed per 0.1 mg, limit $81.13, MUE 10. Report the code whose descriptor matches the product and setting in the record.
Which Medicare coverage articles mention J2778?
1 current Billing and Coding Article in the Medicare Coverage Database lists J2778, covering 5 states: A52451 (Billing and Coding: Ranibizumab, Aflibercept and biosimilars).
What diagnosis codes support J2778?
One Medicare billing and coding article lists 230 covered ICD-10-CM codes for J2778, for example E08.311 (Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema); E08.319 (Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema); E08.3211 (Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye); E08.3212 (Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye); E08.3213 (Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- HCPCS Level II alpha-numeric file, October 2026Version October 2026 · effective 2026-10-01 · file HCPC2026_OCT_ANWEB_09232026.txtSHA-256 c25240c63108756d…
- Medicare Part B Drug Payment Limit File, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 Medicare Part B Payment Limit File 091626.csvSHA-256 508fba376a29e099…
- Medicare Part B Drug Payment Limit File, July 2026Version July 2026 · effective 2026-07-01 · file section 508 version of July 2026 Medicare Part B Payment Limit File updated 082026.csvSHA-256 13bb5b644b92b574…
- ASP NDC-HCPCS Crosswalk, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 ASP NDC-HCPCS Crosswalk 091126.csvSHA-256 5cb78f0c2ee786ba…
- NCCI MUE table, practitioner services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_PractitionerServices_Eff_10-01-2026.csvSHA-256 ef038efaf902b7bd…
- NCCI MUE table, facility services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_OutpatientHospitalServices_Eff_10-01-2026.csvSHA-256 3af9f4e99cc587e2…
- NCCI MUE table, dme services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_DMESupplierServices_Eff_10-01-2026.csvSHA-256 6fa4fbba852f7b74…
- NCCI PTP edits, practitioner, v323r0 (four files)Version v323r0 (2026 Q4) · effective 2026-10-01 · file ccipra-v323r0-f1.TXTSHA-256 7793c0b6686c1e22…
- NCCI Add-On Code edits, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file AOC_V2026Q4-F-MCR.xlsxSHA-256 eabb519623134549…
- OPPS Addendum B, October 2026Version October 2026 · effective 2026-10-01 · file 508-compliant-version-2026_October_Web_Addendum_B.09.28.26.csvSHA-256 6ad7393a318bf1b9…
- ASC Addendum BB (covered ancillary services), October 2026Version October 2026 · effective 2026-10-01 · file Oct 2026 ASC BB.txtSHA-256 63cdd7c72aba7a25…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.